1
|
Forslund M, Melin J, Stener‐Victorin E, Hirschberg AL, Teede H, Vanky E, Piltonen T. International evidence-based guideline on assessment and management of PCOS-A Nordic perspective. Acta Obstet Gynecol Scand 2024; 103:7-12. [PMID: 37983875 PMCID: PMC10755126 DOI: 10.1111/aogs.14725] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 10/23/2023] [Accepted: 11/04/2023] [Indexed: 11/22/2023]
Abstract
Polycystic ovary syndrome (PCOS) affects about 12% of women of reproductive age. In 2018, the first evidence-based guideline on assessment and management of PCOS was published, and an updated extended guideline was released in August 2023. These guidelines followed best practice and are endorsed by 39 organizations worldwide, making them the most robust source of evidence to guide clinical practice. In the 2023 guideline, diagnostic criteria have been further refined as polycystic ovary morphology can now be assessed with gynecological ultrasound or elevated anti-Müllerian hormone levels. A healthy lifestyle should be at the focus of care for all women with PCOS; however, with no specific diet or physical exercise recommended. The latest evidence on medical treatments and fertility management are reviewed, including special considerations regarding long-term follow-up of metabolic and psychiatric comorbidities and pregnancy in women with PCOS. Here we summarize the recommendations from a Nordic perspective.
Collapse
Affiliation(s)
- Maria Forslund
- Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden
- Department of Gynecology and ObstetricsSahlgrenska University HospitalGothenburgSweden
| | - Johanna Melin
- Department of Obstetrics and GynecologyUniversity of Helsinki, Helsinki University HospitalHelsinkiFinland
| | | | - Angelica Linden Hirschberg
- Department of Women's and Children's HealthKarolinska InstitutetStockholmSweden
- Department of Gynecology and Reproductive MedicineKarolinska University HospitalStockholmSweden
| | - Helena Teede
- Monash Centre for Health Research & Implementation, Faculty of Medicine, Nursing and Health SciencesMonash UniversityMelbourneVictoriaAustralia
- Endocrine and Diabetes Units, Monash HealthMelbourneVictoriaAustralia
| | - Eszter Vanky
- Department of Clinical and Molecular Medicine, Faculty of Medicine and Health SciencesNorwegian University of Science and TechnologyTrondheimNorway
- Department of Obstetrics and GynecologySt Olav's University HospitalTrondheimNorway
| | - Terhi Piltonen
- Department of Obstetrics and Gynecology, Research Unit of Clinical MedicineUniversity of Oulu and Oulu University HospitalOuluFinland
| |
Collapse
|
2
|
Tschaidse L, Reisch N, Arlt W, Brac de la Perriere A, Linden Hirschberg A, Juul A, Mallappa A, Merke DP, Newell-Price JDC, Perry CG, Prete A, Rees DA, Stikkelbroeck NMML, Touraine PA, Coope H, Porter J, Ross RJM, Quinkler M. Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia. Eur J Endocrinol 2023; 188:6991929. [PMID: 36654495 DOI: 10.1093/ejendo/lvac006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2022] [Revised: 11/06/2022] [Accepted: 11/30/2022] [Indexed: 01/20/2023]
Abstract
OBJECTIVE Poorly controlled salt-wasting (SW) congenital adrenal hyperplasia (CAH) patients often require high 9α-fluorocortisol doses as they show high levels of 17-hydroxyprogesterone (17OHP), which is a mineralocorticoid (MC)-receptor antagonist. DESIGN We investigated the renin-angiotensin-aldosterone system in patients with SW-CAH receiving twice daily modified-release hydrocortisone (MR-HC, Efmody) compared with standard glucocorticoid (GC) therapy. METHODS Data were analyzed from the 6-month, phase 3 study of MR-HC (n = 42) versus standard GC therapy (n = 41). MC replacement therapy remained unchanged throughout the study. Blood pressure, serum potassium, serum sodium, plasma renin activity (PRA), and serum 17OHP and androstenedione concentrations were analyzed at baseline, 4, 12, and 24 weeks. RESULTS The median serum 17OHP in the morning was significantly lower on MR-HC compared with standard GC at 24 weeks (2.5 nmol L-1 (IQR 8.3) versus 10.5 nmol L-1 (IQR 55.2), P = .001). PRA decreased significantly from baseline to 24 weeks in patients on MR-HC (0.83 ng L-1 s-1 (IQR 1.0) to 0.48 ng L-1 s-1 (IQR 0.61), P = .012) but not in patients on standard GC (0.53 ng L-1 s-1 (IQR 0.66) to 0.52 ng L-1 s-1 (IQR 0.78), P = .613). Serum sodium concentrations increased from baseline to 24 weeks in patients on MR-HC (138.8 ± 1.9 mmol L-1 to 139.3 ± 1.8 mmol L-1, P = .047), but remained unchanged on standard GC (139.8 ± 1.6 mmol L-1 to 139.3 ± 1.9 mmol L-1, P = .135). No significant changes were seen in systolic and diastolic blood pressure and serum potassium levels. CONCLUSION 6 months of MR-HC therapy decreased PRA and increased sodium levels indicating a greater agonist action of the 9α-fluorocortisol dose, which may be due to the decreased levels of the MC-receptor antagonist 17OHP.
Collapse
Affiliation(s)
- Lea Tschaidse
- Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
| | - Nicole Reisch
- Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
| | - Wiebke Arlt
- Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, United Kingdom
| | - Aude Brac de la Perriere
- Hospices Civils de Lyon, Fédération d'Endocrinologie, Groupement hospitalier Est, Bron Cedex, France
| | - Angelica Linden Hirschberg
- Department of Women's and Children's Health, Karolinska Institutet and Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - Anders Juul
- Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Ashwini Mallappa
- AstraZeneca, Gaithersburg, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
| | - Deborah P Merke
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, United States
| | | | - Colin G Perry
- Queen Elizabeth University Hospital, Glasgow, United Kingdom
| | - Alessandro Prete
- Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, United Kingdom
| | - D Aled Rees
- Neuroscience and Mental Health Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom
| | | | - Philippe A Touraine
- University Hospitals Pitié Salpêtrière - Charles Foix, Center for Rare Endocrine and Gynecological Disorders, Paris, France
| | | | | | | | | |
Collapse
|
3
|
Merke DP, Mallappa A, Arlt W, De La Perriere AB, Hirschberg AL, Juul A, Newell-Price JDC, Perry CG, Prete A, Rees A, Reisch N, Stikkelbroeck M, Touraine PA, Coope HJ, Porter J, Ross RJ. RF09 | PSAT70 Comparison of Prednisolone Versus Modified-release Hydrocortisone (Efmody) in the Treatment of Congenital Adrenal Hyperplasia (CAH). J Endocr Soc 2022. [DOI: 10.1210/jendso/bvac150.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Abstract
Background
Prednisolone and prednisone have a longer plasma elimination half-life after oral administration than hydrocortisone: 2.1 to 3.5 vs ∼1.5hrs1,2. For this reason, prednis(ol)one has been used in Congenital Adrenal Hyperplasia (CAH) by giving a dose in the evening to try to prevent the overnight rise in adrenal androgens. Modified-release hydrocortisone (MRHC) capsules, (Efmody, Diurnal Ltd, Cardiff UK), replicate the cortisol diurnal rhythm and improve the control of CAH compared to standard glucocorticoid therapy3. This post-hoc sub-analysis examines CAH control in MRHC treated patients switched from prednis(ol)one.
Methods
We reviewed the data of all patients taking prednis(ol)one in the randomised study of standard treatment versus MRHC3: 39 classic CAH patients on prednis(ol)one (alone or combined with hydrocortisone) (36 prednisolone; 3 prednisone) were randomised either to continue prednis(ol)one or switched to MRHC at the same hydrocortisone dose equivalent (HDE=prednisolone dose x5). Patients were assessed after 4 weeks following which blinded dose titration according to 17OHP and A4 control was performed to bring 17OHP into the optimal range (<36 nmol/l) and A4 into the reference range. After 24 weeks, 31 patients from the prednis(ol)one prior therapy group participated in an ongoing MHRC single arm extension study with 28 patients completing 18 months follow up. Control of CAH was defined as a 0900h 17OHP <36 nmol/l.
Results
Median baseline dose (HDE) was 30mg (n=39), androgen control was 56%. In patients randomised to MRHC (n=18), 39% were controlled at baseline and 94% at 4 weeks without dose adjustment. At 24 weeks, after androgen-control guided titration, the HDE dose in the prednis(ol)one group was 34mg, and in the MRHC group 27.5mg, with control being 71% and 94%, respectively. Percentage inhibition of 9am 17OHP from the levels at baseline to that at 24 weeks in the prednis(ol)one group was 32% and in the MRHC group 91%. In this study period there were no adrenal crises in the MRHC group and one in the prednis(ol)one group. MRHC-treated patients in the extension study were further titrated according to clinician assessment, at interim analysis the median MRHC dose was 20mg (median reduction 10mg) and 82% of patients were controlled at 18 months (n=28). In the ongoing extension study of all patients on MRHC (221 patient years), there were 12 adrenal crises in 5 patients (5.4/100 patient years).
Conclusions
Control of CAH is better on MRHC than prednisolone: 94% vs 39%; and the dose of MRHC can be down titrated to an adrenal replacement dose whilst maintaining control in the majority (82%) of patients.
References
1. Pickup ME. Clin Pharmacokinet 1979 4 111-128; 2. Toothaker RD. J Pharm Sci 1982 71 573-576; 3. Merke DP. JCEM 2021 106 e2063-e2077.
Presentation: Saturday, June 11, 2022 1:00 p.m. - 1:05 p.m., Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.
Collapse
|
4
|
Kasielska-Trojan A, Manning JT, Jabłkowski M, Białkowska-Warzecha J, Hirschberg AL, Antoszewski B. Author Correction: Digit ratios and their asymmetries as risk factors of developmental instability and hospitalization for COVID-19. Sci Rep 2022; 12:8677. [PMID: 35606541 PMCID: PMC9126096 DOI: 10.1038/s41598-022-12900-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- A Kasielska-Trojan
- Plastic, Reconstructive and Aesthetic Surgery Clinic, Institute of Surgery, Medical University of Lodz, Kopcinskiego 22, 90-153, Lodz, Poland.
| | - J T Manning
- Applied Sports, Technology, Exercise, and Medicine (A-STEM), Swansea University, Swansea, UK
| | - M Jabłkowski
- Department of Infectious and Liver Diseases, Medical University of Lodz, Lodz, Poland
| | - J Białkowska-Warzecha
- Department of Infectious and Liver Diseases, Medical University of Lodz, Lodz, Poland
| | - A L Hirschberg
- Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - B Antoszewski
- Plastic, Reconstructive and Aesthetic Surgery Clinic, Institute of Surgery, Medical University of Lodz, Kopcinskiego 22, 90-153, Lodz, Poland
| |
Collapse
|
5
|
Kasielska-Trojan A, Manning JT, Jabłkowski M, Białkowska-Warzecha J, Hirschberg AL, Antoszewski B. Digit ratios and their asymmetries as risk factors of developmental instability and hospitalization for COVID-19. Sci Rep 2022; 12:4573. [PMID: 35301404 PMCID: PMC8931101 DOI: 10.1038/s41598-022-08646-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Accepted: 03/08/2022] [Indexed: 01/08/2023] Open
Abstract
COVID-19 presents with mild symptoms in the majority of patients but in a minority it progresses to acute illness and hospitalization. Here we consider whether markers for prenatal sex hormones and postnatal stressors on developmental instability, i.e. digit ratios and their directional and unsigned asymmetries, are predictive of hospitalization. We focus on six ratios: 2D:3D; 2D:4D; 2D:5D; 3D:4D; 3D:5D; 4D:5D and compare hospitalized patient and control means for right, and left ratios, directional asymmetries (right–left) and unsigned asymmetries [|(right–left)|]. There were 54 patients and 100 controls. We found (i) patients differed in their digit ratios from controls (patients > controls) in all three ratios that included 5D (2D:5D, 3D:5D and 4D:5D) with small to medium effect sizes (d = 0.3 to 0.64), (ii) they did not differ in their directional asymmetries, and (iii) patients had greater |(right–left)| asymmetry than controls for 2D:4D (d = .74) , and all ratios that included 5D; 2D:5D (d = 0.66), 3D:5D (d = .79), 4D:5D (d = 0.47). The Composite Asymmetry of the two largest effects (2D:4D + 3D:5D) gave a patient and control difference with effect size d = 1.04. All patient versus control differences were independent of sex. We conclude that digit ratio patterns differ between patients and controls and this was most evident in ratios that included 5D. Large |(right–left)| asymmetries in the patients are likely to be a marker for postnatal stressors resulting in developmental perturbations and for potential severity of COVID-19.
Collapse
Affiliation(s)
- A Kasielska-Trojan
- Plastic, Reconstructive and Aesthetic Surgery Clinic, Institute of Surgery, Medical University of Lodz, Kopcinskiego 22, 90-153, Lodz, Poland.
| | - J T Manning
- Applied Sports, Technology, Exercise, and Medicine (A-STEM), Swansea University, Swansea, UK
| | - M Jabłkowski
- Department of Infectious and Liver Diseases, Medical University of Lodz, Lodz, Poland
| | - J Białkowska-Warzecha
- Department of Infectious and Liver Diseases, Medical University of Lodz, Lodz, Poland
| | - A L Hirschberg
- Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - B Antoszewski
- Plastic, Reconstructive and Aesthetic Surgery Clinic, Institute of Surgery, Medical University of Lodz, Kopcinskiego 22, 90-153, Lodz, Poland
| |
Collapse
|
6
|
Merke DP, Mallappa A, Arlt W, de la Perriere AB, Hirschberg AL, Juul A, Newell-Price JDC, Perry CG, Prete A, Rees A, Reisch N, Stikkelbroeck M, Touraine PA, Maltby K, Treasure P, Porter J, Ross RJM. OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia. J Endocr Soc 2020. [PMCID: PMC7209435 DOI: 10.1210/jendso/bvaa046.214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes related to inadequate glucocorticoid (GC) replacement. We compared disease control of adults with classic CAH treated with a modified release hydrocortisone (MRHC), which replicates physiological diurnal cortisol secretion, versus standard GC therapy. Methods: 6 month, open label, study in 122 patients randomised either to treatment with MRHC (Chronocort®, Diurnal Ltd, Cardiff, UK) twice daily at ~ 0700h & ~2300h, or to remain on their standard GC regimen (hydrocortisone, prednisolone, prednisone, dexamethasone). Patients had 24-hr profiling of serum 17-hydroxyprogesterone (17-OHP) at baseline and for dose titration at 4 and 12 weeks. The primary efficacy endpoint was the change from baseline to 24 weeks in the natural logarithm of the mean of the 24-hr standard deviation score (SDS) profile for 17-OHP. Results: Both groups achieved improved hormonal control at 24 weeks. The mean 24-hour 17-OHP SDS was significantly lower on MRHC compared to standard GC at 4 weeks (p = 0.0074) and 12 weeks (p = 0.019), but not at 24 weeks. In post-hoc analyses at 24 weeks, MRHC treatment showed a greater reduction in 17-OHP SDS compared to standard GC in the morning, 0700-1500h (p = 0.0442) and a greater reduction in log transformed 17-OHP 24 hour AUC (p=0.0251). Defining a morning 17-OHP <1200ng/dl (<36 nmol/L) as good control, for patients not controlled at baseline 85% were well controlled at 24 weeks with MHRC versus 50% on standard GC. For patients controlled at baseline 100% were controlled at 24 weeks on MHRC versus 84% with standard GC (p = 0.0018). The variability of 17-OHP over 24 hours was significantly reduced in the MRHC group compared to standard GC: the ratio of amplitude at 24 weeks divided by amplitude at baseline was for MRHC, 0.361 [95% CI: 0.235, 0.651], and standard GC, 0.917 [0.773, 1.366]; (p = 0.0001).There were no adrenal crises on MRHC and fewer stress doses despite similar incidence of inter-current illness to the standard GC group which had 3 adrenal crises. MRHC was associated with patient reported benefit including restoration of menstruation in 4 patients on MRHC and 1 on standard GC and two partner pregnancies in patients on MRHC and none on standard GC. Discussion: This is the largest randomised controlled trial of GC treatment in CAH and showed that intensification of therapy could improve control of the androgen-precursor, 17-OHP, and that this hormonal control was superior in the morning with MRHC. MRHC reduced the fluctuations in 17-OHP such that in the majority of patients the 17-OHP profile was within the reference range throughout 24 hours, providing consistent and optimal disease control. Conclusion: Diurnal cortisol replacement with a MRHC improves the biochemical control of classic CAH with a twice-daily therapeutic regimen.
Collapse
Affiliation(s)
| | | | - Wiebke Arlt
- Univ of Birmingham, Birmingham, United Kingdom
| | | | | | | | | | | | | | - Aled Rees
- Cardiff University, Cardiff, United Kingdom
| | - Nicole Reisch
- Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
| | | | | | | | | | | | | |
Collapse
|
7
|
Falhammar H, Frisén L, Hirschberg AL, Nordenskjöld A, Almqvist C, Nordenström A. Increased Risk of Autoimmune Disorders in 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. J Endocr Soc 2019; 3:1039-1052. [PMID: 31065621 PMCID: PMC6497917 DOI: 10.1210/js.2019-00122] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Accepted: 04/04/2019] [Indexed: 12/28/2022] Open
Abstract
Context The prevalence of autoimmune disorders in individuals with 21-hydroxylase deficiency (21OHD) is unclear. The gene responsible, CYP21A2, is located in a highly immunologically active region. Objective To study the prevalence of autoimmune disorders in individuals with 21OHD. Design, Setting, and Participants Patients with 21OHD (n = 714) were compared with controls matched for sex, year, and place of birth (n = 71,400). Data were derived by linking National Population-Based Registers. Subgroup analyses were performed regarding phenotype and CYP21A2 genotype. Main Outcome Measures Number and type of autoimmune disorders. Results Mean age (± SD) was 29.8 ± 18.4 years. Individuals with 21OHD had more autoimmune disorders than did controls [7.4% vs 5.1%, P < 0.01; relative risk (RR) 1.47 (95% CI, 1.13 to 1.91)], especially male patients [6.8% vs 4.1%, P < 0.05; RR, 1.64 (95% CI, 1.08 to 2.49)], whereas it did not reach significance for female patients [7.9% vs 5.8%, P = 0.068; RR, 1.37 (95% CI, 0.98 to 1.92)]. Among the specific autoimmune groups and disorders, autoimmune endocrine disorders and autoimmune thyroid disorders, including Graves disease, were significantly increased in the entire cohort of patients and for male and female patients separately. Inflammatory bowel disease (IBD) and systemic connective tissue disorders did not reach significant levels for the entire cohort (P = 0.075 and 0.05, respectively), but male patients were more affected by IBD (P = 0.022). The groups with milder phenotypes and genotypes seemed to be more affected by autoimmune disorders. Conclusions 21OHD was associated with an increased prevalence of autoimmune disorders. The relatively young age of the patient cohort and possible protective effects by glucocorticoid treatment may have underestimated the risk.
Collapse
Affiliation(s)
- Henrik Falhammar
- Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.,Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
| | - Louise Frisén
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.,Child and Adolescent Psychiatry Research Center, Stockholm, Sweden
| | - Angelica Linden Hirschberg
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.,Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - Agneta Nordenskjöld
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.,Pediatric Surgery, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
| | - Catarina Almqvist
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.,Lung and Allergy Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital Stockholm, Sweden
| | - Anna Nordenström
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.,Department of Pediatric Endocrinology, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
8
|
Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, Antolín-Novoa S, García-Estévez L, Bermejo de las Heras B, Presa-Lorite J, Sánchez-Vigil de la Villa I, Suárez-Almarza J, Nieto-Magro C. Abstract P3-12-01: 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study”. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-12-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: 0.005% Estriol vaginal gel is a new formulation for the local treatment of postmenopausal vaginal atrophy which delivers an ultra-low dose of estriol (50mcg) per application. A study is proposed with the hypothesis that 0.005% Estriol vaginal gel is an efficacious and safe option to treat moderate to severe symptoms of vaginal atrophy caused by AIs without producing significant decline in gonadotropins or increase in systemic estrogens.
METHODS: 70 women with breast cancer receiving AIs and suffering from moderate to severe symptoms of vaginal atrophy were randomized to receive 1g of estriol gel or placebo gel (4:1) daily for 3 weeks and twice weekly up to 12 weeks. Preliminary data from an initial phase comprising 10 women treated for 3 weeks suggested that 0.005% Estriol vaginal gel did not have an influence on hypophyseal axis or estrogens. In the second study phase planned in 60 women, vaginal dryness and other symptoms and signs were analyzed with a 4-point severity scale (none, mild, moderate, severe) at baseline and at weeks 3 and 12. Estriol (E3), estradiol (E2) and estrone (E1) were analyzed by ultrasensitive LC-MS/MS assay (LOQ: 1pg/ml, 3pg/ml and 5pg/ml for E3, E2 and E1, respectively) at baseline and at weeks 1, 3, 8 and 12. FSH and LH were determined by Chemiluminiscency at the same timepoints and also at screening. Changes in vaginal parameters and hormonal levels were assessed. Adverse events were collected.
RESULTS: 61 women aged 59.2 (7.1) from 5 sites in Spain and Karolinska University Hospital in Sweden comprised the ITT analysis. At baseline, all women but one were treated with anastrozole or letrozole. One-third complained from moderate and two-thirds from severe vaginal dryness. 50 received estriol and 11 placebo. Women that received estriol slightly increased E3 levels [median (Q25-Q75)] to 3.9 (0.5-12.1), 1.9 (0.5-6.8), 0.5 (0.5-6.0) and 0.5 (0.5-7.3) pg/ml at w1, w3, w8 and w12 respectively. In these women E2 and E1 remained below LOQ in all samples but one at w12. Variation of FSH between baseline and w12 was not different from the variation of FSH before treatment (p=0.11 Wilcoxon), while small oscillations were observed between baseline and w1 and baseline and w3 as compared to FSH variation before treatment (p<0.05 Friedman, Dunn's correction). A clinical superiority was observed at the end of treatment in women that received estriol in the improvement of their vaginal dryness,vaginal maturation value and score of vaginal signs vs those that received placebo ( p<0.01, p=0.01, p<0.01, respectively, Mann-Whitney-Wilcoxon). One serious adverse event emerged before the patient initiated treatment.
CONCLUSIONS: These data confirm the efficacy of 0.005% Estriol vaginal gel in women with breast cancer suffering from bothersome vaginal symptoms, with a transitory negligible absorption of estriol in initial weeks and a non-significant variation of FSH after 12 weeks of treatment. These findings provide confidence for the safe use of 0.005% Estriol vaginal gel in women with breast cancer with an indication for vaginal symptoms improvement.
Citation Format: Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, Antolín-Novoa S, García-Estévez L, Bermejo de las Heras B, Presa-Lorite J, Sánchez-Vigil de la Villa I, Suárez-Almarza J, Nieto-Magro C. 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study” [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-12-01.
Collapse
Affiliation(s)
- P Sánchez-Rovira
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| | - AL Hirschberg
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| | - M Gil-Gil
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| | - S Antolín-Novoa
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| | - L García-Estévez
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| | - B Bermejo de las Heras
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| | - J Presa-Lorite
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| | - I Sánchez-Vigil de la Villa
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| | - J Suárez-Almarza
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| | - C Nieto-Magro
- Complejo Hospitalario de Jaén, Jaén, Spain; Karolinska University Hospital, Stockholm, Sweden; Institut Català D' Oncologia (I.C.O.), Barcelona, Spain; Complejo Hospitalario Universitario A Coruña, La Coruña, Spain; Hospital HM Universitario Sanchinarro, Madrid, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; GEICAM - Spanish Breast Cancer Group, Madrid, Spain; ITF Research Pharma S.L.U, Madrid, Spain
| |
Collapse
|
9
|
Falhammar H, Frisén L, Norrby C, Almqvist C, Hirschberg AL, Nordenskjöld A, Nordenström A. Reduced Frequency of Biological and Increased Frequency of Adopted Children in Males With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. J Clin Endocrinol Metab 2017; 102:4191-4199. [PMID: 28945916 DOI: 10.1210/jc.2017-01139] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Accepted: 09/08/2017] [Indexed: 02/13/2023]
Abstract
CONTEXT Fertility in males with 21-hydroxylase deficiency (21OHD) is unclear. OBJECTIVE Study fertility outcome in males with congenital adrenal hyperplasia. DESIGN, SETTING, AND PARTICIPANTS Males ≥15 years old with 21OHD (n = 221) were compared with controls matched for sex and year and place of birth (n = 22,024). Data were derived by linking national population-based registers. Subgroup analyses were performed regarding phenotype [salt-wasting (SW), simple virilizing (SV), and nonclassic (NC)] and CYP21A2 genotype (null, I2 splice, I172N, and P30L) and stratified by the introduction of neonatal screening. MAIN OUTCOME MEASURES Number of biological and adopted children. RESULTS Males with 21OHD were less likely to be fathers of biological children [odds ratio (OR), 0.5; 95% confidence interval (CI), 0.4 to 0.7; after adjusting for socioeconomic characteristics: OR, 0.4; 95% CI, 0.2 to 0.5]. This was true for SW, SV, I2 splice, and I172N, but not for NC, null, and P30L groups (all adjusted). Among patients born before the neonatal screening introduction, fewer were fathers (adjusted OR, 0.3; 95% CI, 0.2 to 0.5), but this normalized in those born afterward. Adoption was more common in the 21OHD males (OR, 2.9; 95% CI, 1.0 to 7.9) and the SV and I172N subgroups. Age at becoming a father, marriage, region of residence, and education were similar, but fewer patients had high incomes. NC and I172N groups had, however, higher academic degrees and NC patients were more often married, whereas SW and I2 splice patients were more often divorced. CONCLUSIONS 21OHD was associated with a reduced frequency of biological children and an increased frequency of adopted children, suggesting impaired fertility, although some subgroups had normal fertility.
Collapse
Affiliation(s)
- Henrik Falhammar
- Department of Endocrinology, Metabolism, and Diabetes, Karolinska University Hospital, SE-171 76 Stockholm, Sweden
- Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 76 Stockholm, Sweden
| | - Louise Frisén
- Department of Clinical Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden
- Child and Adolescent Psychiatry Research Center, SE-171 77 Stockholm, Sweden
| | - Christina Norrby
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 64 Stockholm, Sweden
| | - Catarina Almqvist
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 64 Stockholm, Sweden
- Lung and Allergy Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| | - Angelica Linden Hirschberg
- Department of Women's and Children's Health, Karolinska Institutet, SE-171 76 Stockholm, Sweden
- Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, SE-171 76 Stockholm, Sweden
| | - Agneta Nordenskjöld
- Department of Women's and Children's Health, Karolinska Institutet, SE-171 76 Stockholm, Sweden
- Center for Molecular Medicine, Karolinska Institutet, SE-171 76 Stockholm, Sweden
- Pediatric Surgery, Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| | - Anna Nordenström
- Department of Women's and Children's Health, Karolinska Institutet, SE-171 76 Stockholm, Sweden
- Department of Pediatric Endocrinology, Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| |
Collapse
|
10
|
Ohlsson Gotby A, Nordenström A, Falhammar H, Nordenskjöld A, Linden Hirschberg A, Frisén L, Landén M, Lichtenstein P. Congenital Adrenal Hyperplasia, Polycystic Ovary Syndrome and criminal behavior: A Swedish population based study. Psychiatry Res 2015; 229:953-9. [PMID: 26254797 DOI: 10.1016/j.psychres.2015.07.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Revised: 06/15/2015] [Accepted: 07/05/2015] [Indexed: 10/23/2022]
Abstract
Both prenatal and circulating testosterone and other androgens have been suggested to influence the individual's propensity to commit crime, but empirical evidence is limited and inconsistent. Congenital Adrenal Hyperplasia (CAH) and Polycystic Ovary Syndrome (PCOS) are both hyperandrogenic conditions but with an important difference; whereas subjects with CAH are exposed to high concentrations of androgens in utero, women with PCOS are subjected to high androgens in adulthood. Comparing these groups can therefore yield important insights of androgenic effects on behavior. In the current study, information on medical diagnoses and convicted crimes were gathered from Swedish population-based registers. The associations between diagnoses of CAH or PCOS and any crime, violent crime or sex crime were estimated with conditional logistic regression. Results showed that CAH in women and men did not predict criminality, whereas an increased risk for any crime and violent crime was found in PCOS women. Our findings indicate that female hyperandrogenism in adulthood, but not prenatal hyperandrogenism, is associated with risk for criminal behavior. Further research into hyperandrogenic conditions holds opportunities to deepen our understanding of the etiology of crime and psychopathology.
Collapse
Affiliation(s)
- Agnes Ohlsson Gotby
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden.
| | - Anna Nordenström
- Departments of Molecular Medicine and Surgery, Karolinska University Hospital, Solna (L1:00), SE-171 76 Stockholm, Sweden; Department of Pediatric Endocrinology, Astrid Lindgren Children Hospital, Karolinska University Hospital, SE- 171 76 Stockholm, Sweden
| | - Henrik Falhammar
- Departments of Molecular Medicine and Surgery, Karolinska University Hospital, Solna (L1:00), SE-171 76 Stockholm, Sweden; Department of Endocrinology, Metabolism, and Diabetes, Karolinska University Hospital, SE-171 76 Stockholm, Sweden
| | - Agneta Nordenskjöld
- Department of Women's and Children's Health, Karolinska Institutet, SE-171 76 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, SE-171 76 Stockholm, Sweden; Department of Pediatric Surgery, Astrid Lindgren Children Hospital, Karolinska University Hospital, SE-171 76 Stockholm, Sweden
| | - Angelica Linden Hirschberg
- Department of Women's and Children's Health, Karolinska Institutet, SE-171 76 Stockholm, Sweden; Department of Obstetrics and Gynaecology, Karolinska University Hospital, SE-171 76, Stockholm, Sweden
| | - Louise Frisén
- Department of Clinical Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden; Child and Adolescent Psychiatry Research Center, Karolinska Institutet, SE-171 77 Stockholm, Sweden
| | - Mikael Landén
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden; Institute of Neuroscience and Physiology, University of Gothenburg, Box 430, SE-405 30 Gothenburg, Sweden
| | - Paul Lichtenstein
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE-171 77 Stockholm, Sweden
| |
Collapse
|
11
|
Falhammar H, Frisén L, Hirschberg AL, Norrby C, Almqvist C, Nordenskjöld A, Nordenström A. Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. J Clin Endocrinol Metab 2015; 100:3520-8. [PMID: 26126207 DOI: 10.1210/jc.2015-2093] [Citation(s) in RCA: 122] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
CONTEXT Congenital adrenal hyperplasia (CAH) is lethal in its most severe forms if not treated with glucocorticoids. However, glucocorticoids may increase the risk of cardiovascular and metabolic morbidity. OBJECTIVE This study aimed to study cardiovascular and metabolic morbidity in CAH. DESIGN, SETTING, AND PARTICIPANTS Patients with CAH due to 21-hydroxylase deficiency (n = 588; >80% with known CYP21A2 mutations) were compared with controls matched for sex, year, and place of birth (n = 58 800). Data were obtained by linking national population-based registers. Subgroup analyses were performed regarding sex, clinical severity (salt wasting, simple virilizing, nonclassic), CYP21A2 genotype (null, I2 splice, I172N, P30L), and stratified by the introduction of neonatal screening, age groups, and nonobesity. MAIN OUTCOME MEASURES To study cardiovascular and metabolic morbidity in CAH. RESULTS In CAH, both any cardiovascular and metabolic disorders (OR [odds ratio], 3.9; 95% CI [confidence interval], 3.1-5.0), and cardiovascular disease (OR, 2.7; 95% CI, 1.9-3.9) were increased. Separate analyses of the individual diseases showed higher frequencies in CAH of hypertension, hyperlipidemia, atrial fibrillation, venous thromboembolism, obesity, diabetes (mainly type 2), obstructive sleep disorder, thyrotoxicosis, and hypothyroidism. Similar results were seen in the stratified groups. On the subgroup level, females were generally more affected (especially I172N and the nonclassic group), as were males with the null genotype. CONCLUSIONS CAH was associated with excess cardiovascular and metabolic morbidity but the mechanism is not certain as the glucocorticoids were not assessed. Hypothyroidism and obesity may be an effect of close observation. However, more severe conditions were presumably detected equally in patients and controls. Screening for diabetes and other metabolic disorders that increase cardiovascular risk is important.
Collapse
Affiliation(s)
- Henrik Falhammar
- Department of Endocrinology, Metabolism and Diabetes (H.F.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Molecular Medicine and Surgery, SE-171 76 Karolinska Institutet (H.F.), Stockholm, Sweden; Department of Clinical Neuroscience (L.F.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Child and Adolescent Psychiatry Research Center (L.F.), SE-113 30 Stockholm, Sweden; Department of Obstetrics and Gynaecology (A.L.H.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Women's and Children's Health (A.L.H., Ag.N., An.N.), SE-171 76 Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics (C.N., C.A.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Lung and Allergy Unit (C.A.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden; Center for Molecular Medicine (Ag.N.), Karolinska Institutet, SE-171 76 Stockholm, Sweden; and Paediatric Surgery (Ag.N.) and Department of Paediatric Endocrinology (An.N.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| | - Louise Frisén
- Department of Endocrinology, Metabolism and Diabetes (H.F.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Molecular Medicine and Surgery, SE-171 76 Karolinska Institutet (H.F.), Stockholm, Sweden; Department of Clinical Neuroscience (L.F.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Child and Adolescent Psychiatry Research Center (L.F.), SE-113 30 Stockholm, Sweden; Department of Obstetrics and Gynaecology (A.L.H.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Women's and Children's Health (A.L.H., Ag.N., An.N.), SE-171 76 Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics (C.N., C.A.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Lung and Allergy Unit (C.A.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden; Center for Molecular Medicine (Ag.N.), Karolinska Institutet, SE-171 76 Stockholm, Sweden; and Paediatric Surgery (Ag.N.) and Department of Paediatric Endocrinology (An.N.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| | - Angelica Linden Hirschberg
- Department of Endocrinology, Metabolism and Diabetes (H.F.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Molecular Medicine and Surgery, SE-171 76 Karolinska Institutet (H.F.), Stockholm, Sweden; Department of Clinical Neuroscience (L.F.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Child and Adolescent Psychiatry Research Center (L.F.), SE-113 30 Stockholm, Sweden; Department of Obstetrics and Gynaecology (A.L.H.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Women's and Children's Health (A.L.H., Ag.N., An.N.), SE-171 76 Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics (C.N., C.A.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Lung and Allergy Unit (C.A.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden; Center for Molecular Medicine (Ag.N.), Karolinska Institutet, SE-171 76 Stockholm, Sweden; and Paediatric Surgery (Ag.N.) and Department of Paediatric Endocrinology (An.N.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| | - Christina Norrby
- Department of Endocrinology, Metabolism and Diabetes (H.F.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Molecular Medicine and Surgery, SE-171 76 Karolinska Institutet (H.F.), Stockholm, Sweden; Department of Clinical Neuroscience (L.F.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Child and Adolescent Psychiatry Research Center (L.F.), SE-113 30 Stockholm, Sweden; Department of Obstetrics and Gynaecology (A.L.H.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Women's and Children's Health (A.L.H., Ag.N., An.N.), SE-171 76 Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics (C.N., C.A.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Lung and Allergy Unit (C.A.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden; Center for Molecular Medicine (Ag.N.), Karolinska Institutet, SE-171 76 Stockholm, Sweden; and Paediatric Surgery (Ag.N.) and Department of Paediatric Endocrinology (An.N.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| | - Catarina Almqvist
- Department of Endocrinology, Metabolism and Diabetes (H.F.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Molecular Medicine and Surgery, SE-171 76 Karolinska Institutet (H.F.), Stockholm, Sweden; Department of Clinical Neuroscience (L.F.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Child and Adolescent Psychiatry Research Center (L.F.), SE-113 30 Stockholm, Sweden; Department of Obstetrics and Gynaecology (A.L.H.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Women's and Children's Health (A.L.H., Ag.N., An.N.), SE-171 76 Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics (C.N., C.A.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Lung and Allergy Unit (C.A.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden; Center for Molecular Medicine (Ag.N.), Karolinska Institutet, SE-171 76 Stockholm, Sweden; and Paediatric Surgery (Ag.N.) and Department of Paediatric Endocrinology (An.N.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| | - Agneta Nordenskjöld
- Department of Endocrinology, Metabolism and Diabetes (H.F.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Molecular Medicine and Surgery, SE-171 76 Karolinska Institutet (H.F.), Stockholm, Sweden; Department of Clinical Neuroscience (L.F.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Child and Adolescent Psychiatry Research Center (L.F.), SE-113 30 Stockholm, Sweden; Department of Obstetrics and Gynaecology (A.L.H.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Women's and Children's Health (A.L.H., Ag.N., An.N.), SE-171 76 Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics (C.N., C.A.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Lung and Allergy Unit (C.A.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden; Center for Molecular Medicine (Ag.N.), Karolinska Institutet, SE-171 76 Stockholm, Sweden; and Paediatric Surgery (Ag.N.) and Department of Paediatric Endocrinology (An.N.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| | - Anna Nordenström
- Department of Endocrinology, Metabolism and Diabetes (H.F.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Molecular Medicine and Surgery, SE-171 76 Karolinska Institutet (H.F.), Stockholm, Sweden; Department of Clinical Neuroscience (L.F.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Child and Adolescent Psychiatry Research Center (L.F.), SE-113 30 Stockholm, Sweden; Department of Obstetrics and Gynaecology (A.L.H.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; Department of Women's and Children's Health (A.L.H., Ag.N., An.N.), SE-171 76 Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics (C.N., C.A.), Karolinska Institutet, SE-171 77 Stockholm, Sweden; Lung and Allergy Unit (C.A.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden; Center for Molecular Medicine (Ag.N.), Karolinska Institutet, SE-171 76 Stockholm, Sweden; and Paediatric Surgery (Ag.N.) and Department of Paediatric Endocrinology (An.N.), Astrid Lindgren Children's Hospital, Karolinska University Hospital, SE-171 64 Stockholm, Sweden
| |
Collapse
|
12
|
Norling A, Hirschberg AL, Rodriguez-Wallberg KA, Iwarsson E, Wedell A, Barbaro M. Identification of a duplication within the GDF9 gene and novel candidate genes for primary ovarian insufficiency (POI) by a customized high-resolution array comparative genomic hybridization platform. Hum Reprod 2014; 29:1818-27. [PMID: 24939957 PMCID: PMC4093997 DOI: 10.1093/humrep/deu149] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
STUDY QUESTION Can high-resolution array comparative genomic hybridization (CGH) analysis of DNA samples from women with primary ovarian insufficiency (POI) improve the diagnosis of the condition and identify novel candidate genes for POI? SUMMARY ANSWER A mutation affecting the regulatory region of growth differentiation factor 9 (GDF9) was identified for the first time together with several novel candidate genes for POI. WHAT IS KNOWN ALREADY Most patients with POI do not receive a molecular diagnosis despite a significant genetic component in the pathogenesis. STUDY DESIGN, SIZE, DURATION We performed a case–control study. Twenty-six patients were analyzed by array CGH for identification of copy number variants. Novel changes were investigated in 95 controls and in a separate population of 28 additional patients with POI. The experimental procedures were performed during a 1-year period. PARTICIPANTS/MATERIALS, SETTING, METHODS DNA samples from 26 patients with POI were analyzed by a customized 1M array-CGH platform with whole genome coverage and probe enrichment targeting 78 genes in sex development. By PCR amplification and sequencing, the breakpoint of an identified partial GDF9 gene duplication was characterized. A multiplex ligation-dependent probe amplification (MLPA) probe set for specific identification of deletions/duplications affecting GDF9 was developed. An MLPA probe set for the identification of additional cases or controls carrying novel candidate regions identified by array-CGH was developed. Sequencing of three candidate genes was performed. MAIN RESULTS AND THE ROLE OF CHANCE Eleven unique copy number changes were identified in a total of 11 patients, including a tandem duplication of 475 bp, containing part of the GDF9 gene promoter region. The duplicated region contains three NOBOX-binding elements and an E-box, important for GDF9 gene regulation. This aberration is likely causative of POI. Fifty-four patients were investigated for copy number changes within GDF9, but no additional cases were found. Ten aberrations constituting novel candidate regions were detected, including a second DNAH6 deletion in a patient with POI. Other identified candidate genes were TSPYL6, SMARCC1, CSPG5 and ZFR2. LIMITATIONS, REASONS FOR CAUTION This is a descriptive study and no functional experiments were performed. WIDER IMPLICATIONS OF THE FINDINGS The study illustrates the importance of analyzing small copy number changes in addition to sequence alterations in the genetic investigation of patients with POI. Also, promoter regions should be included in the investigation. STUDY FUNDING/COMPETING INTEREST(S) The study was supported by grants from the Swedish Research council (project no 12198 to A.W. and project no 20324 to A.L.H.), Stockholm County Council (E.I., A.W. and K.R.W.), Foundation Frimurare Barnhuset (A.N., A.W. and M.B.), Karolinska Institutet (A.N., A.L.H., E.I., A.W. and M.B.), Novo Nordic Foundation (A.W.) and Svenska Läkaresällskapet (M.B.). The funding sources had no involvement in the design or analysis of the study. The authors have no competing interests to declare. TRIAL REGISTRATION NUMBER Not applicable.
Collapse
Affiliation(s)
- A Norling
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
| | - A L Hirschberg
- Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden
| | - K A Rodriguez-Wallberg
- Department of Clinical Science, Intervention and Technology, Section for Obstetrics and Gynaecology and Fertility Unit, Karolinska University Hospital, Stockholm, Sweden
| | - E Iwarsson
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
| | - A Wedell
- Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden Department of Molecular Medicine and Surgery, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden Centre for Inherited Metabolic Diseases (CMMS), Karolinska University Hospital, Stockholm 171 76, Sweden
| | - M Barbaro
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm 171 76, Sweden Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden Centre for Inherited Metabolic Diseases (CMMS), Karolinska University Hospital, Stockholm 171 76, Sweden
| |
Collapse
|
13
|
Ujvari D, Hulchiy M, Calaby A, Nybacka Å, Byström B, Hirschberg AL. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome. Hum Reprod 2014; 29:1526-35. [PMID: 24842895 DOI: 10.1093/humrep/deu114] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
STUDY QUESTION Does lifestyle intervention aiming at weight loss influence endometrial insulin signaling in overweight/obese women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER Lifestyle intervention up-regulates, both at the mRNA and protein levels, components of insulin signaling in the endometrium of overweight/obese PCOS women, in relation to an improved menstrual pattern. WHAT IS KNOWN ALREADY PCOS is a multifactorial endocrine disorder diagnosed by two of the following three criteria: chronic anovulation, hyperandrogenism and polycystic ovaries. Many women with PCOS also have insulin resistance and obesity. The syndrome is furthermore associated with endometrial cancer and possible alterations in endometrial function and receptivity. STUDY DESIGN, SIZE, DURATION This study assessed the effects of a combined diet and exercise lifestyle intervention for 3 months. PARTICIPANTS/MATERIALS, SETTING, METHODS A group of 20 overweight/obese PCOS women with anovulation, hyperandrogenism and polycystic ovaries were subjected to a combined diet and exercise program for 3 months. Ten body mass index (BMI)-matched regularly menstruating overweight/obese controls, nine normal-weight PCOS women and ten normal-weight controls were also included in the study. In an academic clinical setting, women were examined in mid-follicular phase for endocrine assessment and determination of endometrial levels of mRNA and immunohistochemical staining of insulin signaling molecules (the insulin receptor, insulin receptor substrate-1 (IRS1) and glucose transporter (GLUT) 1 and 4). MAIN RESULTS AND THE ROLE OF CHANCE Women with PCOS exhibited lower levels of IRS1 (P < 0.01) and GLUT4 (P < 0.01) mRNA in their proliferative endometrium than BMI-matched controls. After lifestyle intervention, weight loss averaged 4.7% and the menstrual pattern improved in 65% of the overweight/obese women with PCOS. Levels of IRS1 (P < 0.01) and GLUT1 (P < 0.05) mRNA were significantly up-regulated in the endometrium of those women with improved menstrual function, as were the protein expression levels of pY612IRS1 (the activated IRS1 form, P < 0.05), pS312IRS1 (the inhibitory form of IRS1, P < 0.05) and GLUT1 (P < 0.05). Improvement in the menstrual function of women in the obese/overweight group following the lifestyle intervention was positively correlated with the increase in the endometrial level of IRS1 mRNA (r = 0.63, P < 0.01) and negatively correlated with the change in BMI (r = -0.50, P < 0.05). LIMITATIONS, REASONS FOR CAUTION The number of women in each group was limited, although the power calculation indicated that the number of patients subjected to the lifestyle intervention was sufficient. WIDER IMPLICATIONS OF THE FINDINGS We propose that up-regulation of endometrial IRS1 and GLUT1 in overweight/obese women with PCOS following lifestyle intervention improves the glucose homeostasis and thereby restores the functioning of the endometrium in these women. STUDY FUNDING/COMPETING INTEREST(S) This study was supported financially by the Swedish Research Council (A.L.H., 20324), Karolinska Institutet and the Stockholm County Council. None of the authors has any conflict of interest to declare.
Collapse
|
14
|
Strandqvist A, Falhammar H, Lichtenstein P, Hirschberg AL, Wedell A, Norrby C, Nordenskjöld A, Frisén L, Nordenström A. Suboptimal psychosocial outcomes in patients with congenital adrenal hyperplasia: epidemiological studies in a nonbiased national cohort in Sweden. J Clin Endocrinol Metab 2014; 99:1425-32. [PMID: 24476073 DOI: 10.1210/jc.2013-3326] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Congenital adrenal hyperplasia (CAH), CYP21A2 deficiency, results in cortisol and aldosterone deficiency and increased production of androgens, with a good genotype phenotype correlation. OBJECTIVE The objective of the investigation was to study psychosocial outcomes in relation to clinical severity, CYP21A2 genotype, in men and women. DESIGN This was an epidemiological study with a matched case control design. SETTING The setting of the study was all known CAH patients in Sweden. PARTICIPANTS Five hundred eighty-eight patients, more than 80% with known severity of CAH, and 100 controls per patient matched for sex, year, and place of birth participated in the study. MAIN OUTCOME AND MEASURES Proxies for quality of life were selected: level of education, employment, income, sick leave, disability pension, marriage, and children. RESULTS Women with salt-wasting (SW) CAH had completed primary education less often [odds ratio (OR) 0.3], not explained by neonatal salt crisis or hypoglycemia because the men did not differ from controls. Men and women in the less severe I172N genotype group were more likely to have an academic education (OR 1.8). SW women were more likely to have an income in the top 20th percentile (OR 2.0). Both men and women had more disability pension (OR 1.5) and sick leave (OR 1.7). The men more often had long-lasting employment (OR 3.1). Men were more often (OR 1.6) and women were less often married (OR 0.7). Patients had children less often (OR 0.3). CONCLUSIONS This study shows important outcome differences regarding education; employment; marriage and fertility, depending on sex; and severity of CAH. The mechanisms behind this and the increased risk for sick leave or disability pension in both men and women should be identified to improve medical and psychological care.
Collapse
Affiliation(s)
- A Strandqvist
- Departments of Paediatric Endocrinology (A.S., A.Nordenst.) and Paediatric Surgery (A.Nordensk.), Astrid Lindgren Children Hospital, Departments of Endocrinology, Metabolism, and Diabetes (H.F.) and Women's and Children's Health, and Center for Inherited Metabolic Diseases (A.W.), Karolinska University Hospital, SE-171 76 Stockholm, Sweden; and Departments of Molecular Medicine and Surgery (H.F., A.W.), Medical Epidemiology and Biostatistics (P.L., C.N.), Clinical Neuroscience (L.F.), and Women's and Children's Health (A.S., A.L.H., A.Nordensk., A.Nordenst.), Center for Molecular Medicine (A.Nordensk.), and Child and Adolescent Psychiatry Research Center (L.F.), Karolinska Institutet, SE-171 77 Stockholm, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Norling A, Hirschberg AL, Karlsson L, Rodriguez-Wallberg KA, Iwarsson E, Wedell A, Barbaro M. No mutations in the PSMC3IP gene identified in a Swedish cohort of women with primary ovarian insufficiency. Sex Dev 2014; 8:146-50. [PMID: 24481226 DOI: 10.1159/000357605] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/15/2013] [Indexed: 11/19/2022] Open
Abstract
Ovarian dysfunction before the age of 40 years, characterized by hypergonadotropic hypogonadism and presenting with either primary or secondary amenorrhea, is called primary ovarian insufficiency (POI). POI has a significant genetic component, but the specific genetic cause is often unknown. A novel candidate gene for POI, PSMC3IP, has recently been identified. The aim of this study was to investigate a group of patients with POI for possible PSMC3IP mutations. Therefore, DNA samples from 50 patients with POI of primarily Swedish origin were used in the study, 27 with secondary amenorrhea (median age of diagnosis 23 years) and 23 with primary amenorrhea. Control material consisting of DNA samples from 95 women without POI was used for investigation of novel sequence variants. All exons and intron/exon boundaries of the PSMC3IP gene were analyzed by PCR and sequencing. As a result, no pathogenic mutation in the PSMC3IP gene was detected in the cohort. A previously unreported variant, NM_016556.3:c.337+33A>G, was detected in heterozygous form in 1 patient with secondary amenorrhea, likely constituting a normal variant. Two reported single nucleotide polymorphisms were detected in the cohort at the expected frequency. In conclusion, PSMC3IP gene mutations are not common causes of POI in this Swedish cohort.
Collapse
Affiliation(s)
- A Norling
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | | | | | | | | | | | | |
Collapse
|
16
|
Westgren M, Gemzell Danielsson K, Linden Hirschberg A. The NFOG 2014 congress: a venue for learning and interaction. Acta Obstet Gynecol Scand 2013. [DOI: 10.1111/aogs.12280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Koubaa S, Hällström T, Hagenäs L, Hirschberg AL. Retarded head growth and neurocognitive development in infants of mothers with a history of eating disorders: longitudinal cohort study. BJOG 2013; 120:1413-22. [PMID: 23834532 DOI: 10.1111/1471-0528.12370] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/15/2013] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To characterise early growth and neurocognitive development in children of mothers with a history of eating disorders (ED). DESIGN A longitudinal cohort study. SETTING Child-care centres in Stockholm, Sweden. POPULATION Children born to mothers with previous ED (n = 47) (24 anorexia nervosa, 20 bulimia nervosa, 3 unspecified ED), and controls (n = 65). METHODS Mean values and standard deviation scores of weight and height from birth to 5 years of age and head circumference up to 18 months of age were compared between groups. Neurocognitive development was studied at the age of 5 years by the validated parent questionnaire Five to Fifteen. MAIN OUTCOME MEASURES Head growth and neurocognitive development. RESULTS We previously reported that mothers with a history of ED conceived infants with lower birthweight and head circumference than controls. At 3 months of age, body mass index (BMI) was no longer reduced but mean head circumferences of the children born to mothers with ED were smaller throughout the observation period. Similarly, the longitudinal results of the standard deviation scores of head circumference showed a significant overall group effect with lower levels in both subgroups of ED (anorexia nervosa and bulimia nervosa). The children of the ED mothers also had significantly higher Five to Fifteen scores than controls, reflecting difficulties in language skills. Head circumference at birth correlated with language skills in the children of mothers with ED. CONCLUSION Children of mothers with previous ED demonstrated an early catch-up in BMI, but the average head circumference continued to be delayed until at least 18 months of age. The reduced head growth was related to delayed neurocognitive development.
Collapse
Affiliation(s)
- S Koubaa
- Department of Women's and Children's Health, Division for Obstetrics and Gynaecology, Karolinska Institutet and University Hospital, Stockholm, Sweden
| | | | | | | |
Collapse
|
18
|
Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008; 359:2005-17. [PMID: 18987368 DOI: 10.1056/nejmoa0707302] [Citation(s) in RCA: 354] [Impact Index Per Article: 22.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown. METHODS We conducted a double-blind, placebo-controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 microg of testosterone per day or placebo. Efficacy was measured to week 24; safety was evaluated over a period of 52 weeks, with a subgroup of participants followed for an additional year. The primary end point was the change from baseline to week 24 in the 4-week frequency of satisfying sexual episodes. RESULTS At 24 weeks, the increase in the 4-week frequency of satisfying sexual episodes was significantly greater in the group receiving 300 microg of testosterone per day than in the placebo group (an increase of 2.1 episodes vs. 0.7, P<0.001) but not in the group receiving 150 microg per day (1.2 episodes, P=0.11). As compared with placebo, both doses of testosterone were associated with significant increases in desire (300 microg per day, P<0.001; 150 microg per day, P=0.04) and decreases in distress (300 microg per day, P<0.001; 150 microg per day, P=0.04). The rate of androgenic adverse events - primarily unwanted hair growth - was higher in the group receiving 300 microg of testosterone per day than in the placebo group (30.0% vs. 23.1%). Breast cancer was diagnosed in four women who received testosterone (as compared with none who received placebo); one of the four received the diagnosis in the first 4 months of the study period, and one, in retrospect, had symptoms before undergoing randomization. CONCLUSIONS In postmenopausal women not receiving estrogen therapy, treatment with a patch delivering 300 microg of testosterone per day resulted in a modest but meaningful improvement in sexual function. The long-term effects of testosterone, including effects on the breast, remain uncertain. (ClinicalTrials.gov number, NCT00131495.)
Collapse
Affiliation(s)
- Susan R Davis
- Women's Health Program, Monash University, Alfred Hospital, Prahran, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Fridén C, Hirschberg AL, Saartok T, Bäckström T, Leanderson J, Renström P. The influence of premenstrual symptoms on postural balance and kinesthesia during the menstrual cycle. Gynecol Endocrinol 2003; 17:433-9. [PMID: 14992161 DOI: 10.1080/09513590312331290358] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
Recent studies have indicated an increased incidence of female athletic injuries during the luteal phase and the first days of the menstrual period. The purpose of this study was to investigate whether postural sway and knee-joint kinesthesia very during the menstrual cycle, and whether premenstrual syndrome (PMS) influences postural balance and kinesthesia. A total of 13 subjects with regular menstrual cycles participated in the study. Postural sway and kinesthesia were measured in the early follicular phase, in the ovulation phase and in the mid-luteal phase. Postural sway was measured with an ankle disc placed on a Statometer, and kinesthesia was measured with a specially designed device. Menstrual cycle phases were determined by sex hormone analyses in serum and by luteinizing hormone (LH) detection in urine. The diagnosis of PMS was made prospectively using validated daily symptom ratings. Eight of 13 women were classified as having PMS. These women had a significantly greater postural sway (p = 0.002) and a greater threshold for detection of passive motion in the knee joints (p = 0.05) than women without PMS. A tendency (p = 0.06) towards greater postural sway in the mid-luteal phase was detected among women with PMS. This may explain the finding of an increased incidence of athletic injuries in the luteal phase, reported previously.
Collapse
Affiliation(s)
- C Fridén
- Section of Sports Medicine, Division of Surgical Sciences, Karolinska Institutet, SE-171 76 Stockholm, Sweden
| | | | | | | | | | | |
Collapse
|
20
|
Hirschberg AL, Hagenfeldt K. [Athletic amenorrhea and its consequences. Hard physical training at an early age can cause serious bone damage]. Lakartidningen 1998; 95:5765-70. [PMID: 9889498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Strenuous exercise in women is associated with a high incidence of menstrual dysfunction, including amenorrhoea. Athletic amenorrhoea is most common among long-distance runners and ballet dancers, with a prevalence of up to 66 per cent. It is of hypothalamic origin, the pulsatile release of GnRH (gonadotrophin-releasing hormone) being disturbed during exercise, resulting in low gonadotrophin and oestrogen levels. Accumulated evidence suggests athletic amenorrhoea to be related to energy deficiency or to the eating disorders that are prevalent among athletes. The long-term consequences of amenorrhoea are premature osteoporosis and increased risk of musculoskeletal injury. Elite training in young girls tends to delay pubertal development, resulting in decreased bone mass accumulation and reduced growth potential.
Collapse
Affiliation(s)
- A L Hirschberg
- Medicinska forskningsrådet, Karolinska sjukhuset, Stockholm
| | | |
Collapse
|
21
|
Abstract
Several clinical disorders are strongly influenced by hormones involved in appetite and weight regulation. Obesity and eating disorders are of major importance, because they are associated with severe morbidity and considered to be among the greatest health problems in the Western world today. This review describes recent findings in hormonal regulation of food intake by substances acting both centrally, such as corticotropin-releasing factor, neuropeptide Y and leptin, and peripherally, such as cholecystokinin and somatostatin. Sex hormones and glucocorticoids play an important role in long-term regulation of metabolism. The role of these hormones in appetite and weight changes during life as well as during pregnancy and lactation is discussed. Furthermore, the development of obesity and eating disorders is influenced, in particular, by steroid hormones. Treatment with sex hormones, as in hormone replacement therapy, affects appetite and weight and may have beneficial effects in preventing android obesity. Currently, there is great effort in developing endogenous neurohumoral substances into effective drugs for the treatment of obesity and eating disorders. Leptin and neuropeptide Y analogues are of interest as potential antiobesity agents.
Collapse
Affiliation(s)
- A L Hirschberg
- Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden
| |
Collapse
|
22
|
Abstract
This investigation was undertaken to explore a possible role of the "satiety peptide" cholecystokinin and some other gastrointestinal hormones for changes in appetite and weight during oral contraception. Ten young healthy women attending a youth health care center for contraceptive counseling volunteered for the study. A standardized meal test was used for recordings of appetite and gastrointestinal hormone response before and after 5 months of treatment with a monophasic combined oral contraceptive. Body fat was calculated from measurements of skin-fold thickness. Oral contraceptives caused a suppression of basal levels of serum cholecystokinin, which was correlated to an increase in body fat. Meal-related response of cholecystokinin and appetite were not affected. Serum levels of gastrin and insulin were also unchanged, whereas triglycerides and postprandial glucose levels were elevated. The results suggest a role of cholecystokinin in regulation of body composition. Cholecystokinin stimulates the release of insulin and stimulates lipolysis in adipose tissue. Reduced cholecystokinin levels may, therefore, be related to mild impairment of glucose tolerance and promote body fat storage during oral contraception.
Collapse
Affiliation(s)
- A L Hirschberg
- Department of Obstetrics, Karolinska Hospital, Stockholm, Sweden
| | | | | | | |
Collapse
|
23
|
Lindholm C, Hirschberg AL, Carlström K, von Schoultz B. Altered adrenal steroid metabolism underlying hypercortisolism in female endurance athletes. Fertil Steril 1995; 63:1190-4. [PMID: 7750587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
OBJECTIVE To explore possible changes in adrenal steroid metabolism and androgenic-anabolic status in female endurance athletes as a mechanism for their hypercortisolism. DESIGN Adrenal steroids and androgenic-anabolic factors were studied during basal conditions and in response to ACTH stimulation related to menstrual status. SETTING Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden. PARTICIPANTS Thirteen female elite middle to long distance runners (six eumenorrheic, seven oligoamenorrheic) and seven regularly menstruating controls. INTERVENTIONS Blood samples were collected before and after an injection of 250 micrograms IV synthetic ACTH 1-24. Body weight, height, and body fat were measured. MAIN OUTCOME MEASURES Basal serum concentrations of cortisol, androstenedione (A), DHEA, DHEAS, 17 alpha-hydroxyprogesterone (17-OHP), T, steroid-binding proteins, and insulin-like growth factor I and ACTH-induced response (area under the curve) of cortisol, DHEA, and 17-OHP. RESULTS Oligoamenorrheic athletes had higher basal cortisol and A concentrations compared with healthy controls, whereas basal levels of DHEA and DHEAS were normal. Important findings in the oligoamenorrheic athletes were a significantly lower ratio between the ACTH-induced increments of DHEA and 17-OHP and an increased ratio between basal A and DHEAS. Insulin-like growth factor I was correlated negatively to sex hormone-binding globulin and to the amount of body fat in the combined material. CONCLUSIONS The results indicate a redistribution of adrenal steroid metabolism in favor of glucocorticoid production in female endurance athletes. We suggest that hypercortisolism in female endurance athletes is a physiological adaptation to maintain adequate blood glucose levels during a condition of energy deficiency.
Collapse
Affiliation(s)
- C Lindholm
- Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden
| | | | | | | |
Collapse
|
24
|
Abstract
Strenuous training in women has been shown to cause menstrual dysfunction and decreased bone mineral density. These endocrine and metabolic complications are associated with an insufficient dietary intake and decreased body fat content in female athletes. The present investigation was undertaken to study serum levels of cholecystokinin (CCK), insulin, gastrin, and cortisol in 14 female long-distance runners and 15 sex- and age-matched control subjects during intake of a standardized meal (500 kcal). The athletes showed a decreased response of the "satiety peptide" CCK to the meal and reported increased hunger compared with the control group. Meal-related insulin response was also decreased in the athletes, whereas gastrin levels were comparable to those of controls. Basal levels of glucose were increased in the athletes, but there was no difference in postprandial levels between the groups. Cortisol levels were clearly elevated in the female runners. We conclude that insufficient food intake in female athletes cannot be explained by increased CCK secretion and satiety. Since the athletes reported a larger caloric intake of a normal daily breakfast than the control subjects, the decreased CCK response may instead be explained by an adaptation to increased food intake. The decreased meal-related insulin response may be a reflection of increased insulin sensitivity as an adaptation to physical exercise. However, an impaired peptide secretion cannot be excluded. The role of elevated cortisol levels in the gastrointestinal hormone response needs further investigation.
Collapse
Affiliation(s)
- A L Hirschberg
- Department of Obstetrics and Gynecology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
| | | | | | | |
Collapse
|
25
|
Abstract
The anabolic/catabolic hormone balance in 13 female endurance athletes was studied during basal conditions by comparing their serum concentrations of androgenic and catabolic steroids, growth hormone, insulin-like growth factor 1 (IGF-1) and insulin with corresponding values in 15 matched sedentary controls. Higher cortisol and lower levels sex hormone-binding globulin (SHBG) were found in the athletes, and these differences were enhanced depending on the degree of menstrual disorders. There was a negative correlation between cortisol and SHBG levels. No differences were found in concentrations of androgens, IGF-1 and insulin. The results indicate a normal anabolic activity in oligomenorrheic athletes, but due to their distinct hypercortisolism, the anabolic/catabolic hormone balance is changed to a predominantly catabolic state.
Collapse
Affiliation(s)
- C Lindholm
- Department of Obstetrics and Gynecology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
| | | | | | | |
Collapse
|